BMY · Bristol-Myers Squibb Co. · Stock research

​# BMY — Bristol-Myers Squibb Co.

Current Thesis

The narrative leg is unchanged in kind and changed in condition: a legacy-pharma re-rating built on the 2026-07-30 Q2 print (adjusted EPS $2.04 vs $1.59 consensus, revenue $12.973B vs $11.745B) and a FY2026 guidance reset whose new sales floor of $49.000B sits above the old $47.500B ceiling. Since the last note, both attention legs resolved. The AstraZeneca combination was denied by Reuters on 2026-08-05. The FDA binary resolved early and in the company's favour: accelerated approval of ZENBEXUS (iberdomide) with daratumumab and hyaluronidase-fihj and dexamethasone on 2026-08-13, four days ahead of the 2026-08-17 target action date.

Price did not extend on it. The 2026-08-14 close of $63.83 is below the $64.72 close of 2026-08-07 cited in the prior note and 3.1% under the $65.89 52-week high, with RSI(14) at 55.8 against 71.9 a week earlier. A favourable regulatory outcome absorbed without a new high, into a six-week stretch with no company-guided datapoint, is what a maturing narrative looks like on the tape.

Bullish and bearish views on Bristol-Myers Squibb Co.

The model's bull view on Bristol-Myers Squibb Co. (BMY), in brief: First-in-class approval, delivered ahead of schedule. The bear view: The positive binary produced no new high. Both cases follow in full.

Bull Case

• First-in-class approval, delivered ahead of schedule. ZENBEXUS is the first cereblon E3 ligase modulator (CELMoD) approved, cleared 2026-08-13 for multiple myeloma as early as first relapse. EXCALIBER-RRMM showed MRD-negative complete response of 41% in the ZDd arm (n=207) versus 21% for DVd (n=213), p<0.0001, at 16 months median follow-up (BMS release, 2026-08-13). It is also among the first US approvals in relapsed/refractory myeloma granted on an MRD-negativity endpoint.
• The FY2026 raise was structural, not a single-quarter beat. On 2026-07-30 sales guidance went to $49.000–50.000B from $46.000–47.500B (consensus $47.472B) and adjusted EPS to $6.75–7.00 from $6.05–6.35 (consensus $6.34).
• Mix shift is measurable. Q2 2026 growth-portfolio revenue $7.6B, +14% YoY, approaching 60% of total; Camzyos $416M (+59%), Cobenfy $63M (+81%), Qvantig $261M, Breyanzi +41%, Reblozyl +29% (Q2 call, 2026-07-30).
• Eliquis FY2026 growth outlook raised to 20–25% from 10–15%, against negotiated CMS prices effective 2026-01-01.
• A dated pipeline event survives the window. Camzyos adolescent sNDA (ages 12 to <18, symptomatic oHCM, SCOUT-HCM: mavacamten n=23 vs placebo n=21, primary endpoint met on Valsalva LVOT gradient at week 28) carries a PDUFA date of 2026-09-30.
• Capital deployment into US manufacturing. $2.3B Houston campus announced 2026-08-10, roughly 500 jobs — relevant to the pharma-tariff overhang that has repriced the cohort twice in the past year.

Bear Case

• The positive binary produced no new high. Approval landed 2026-08-13; the 2026-08-14 close was $63.83, still 3.1% below the $65.89 52-week high set before it.
• ZENBEXUS is accelerated, not full, approval. BMS states full approval is contingent on verification of clinical benefit in confirmatory trial(s); progression-free survival, the co-primary endpoint of EXCALIBER-RRMM, has not read out. A negative PFS result is a withdrawal risk, not merely a sentiment risk.
• Camzyos now has a launched competitor and a live lawsuit. Cytokinetics filed a declaratory-judgment action in D. Delaware against BMS and MyoKardia on 2026-08-13 over US Patent No. 12,616,697, seeking non-infringement and invalidity plus an injunction barring BMS from threatening litigation over MYQORZO (aficamten). Camzyos is the fastest-scaling growth asset in the portfolio; its competitive setting is now contested in court.
• Consensus targets sit at spot. MarketBeat's aggregate as of 2026-08-13 shows an average target of $64.92 against a $40–$75 range — roughly 1.7% implied from the $63.83 close. Two of the eight post-print anchors (RBC $64, Cantor $59, both 2026-07-31) are at or below it.
• Reported growth was +5.7% YoY despite the ~10% revenue beat; the surprise measured the bar.
• Patent arithmetic past FY2026 is unresolved and nothing dated inside this window speaks to it.

Setup & Price Structure

The narrative is maturing. The dates that justify the label: attention peaked 2026-08-02/03 on the $400B merger report and was denied 2026-08-05; the guidance raise of 2026-07-30 is now three weeks old and fully in the sell-side numbers; the 2026-08-13 approval was the last dated company event, and it cleared without a breakout. The narrative still works — 3-month return +13.3%, price within 3.1% of the high — but new information arriving per unit of time has fallen sharply, which is moderating flow rather than fresh participation.

Crowding and positioning observables, stated as observables:

• RSI(14) decayed from 71.9 (2026-08-07) to 55.8 (2026-08-14) while price fell from $64.72 to $63.83 — the momentum unwound faster than the price.
• Average analyst target $64.92 versus a $63.83 close (MarketBeat aggregate, 2026-08-13): the sell-side anchor is at market, with the bull cluster at $73–75 (JPMorgan $73, Guggenheim $75, Argus $75) and the bear anchor at $40.
• Retail-facing coverage clustered on 2026-08-02/03 around a merger that Reuters says never existed; that cohort's exit is untracked.
• No earnings date inside 30 days; Q3 2026 is expected late October.
• No Form 4 or registration activity appeared in the filing feed reviewed for the trailing 30 days — no insider-selling or issuance-into-strength signal either way, which is an absence of evidence, not evidence of absence.

Structure to watch: the $61 area marks where the advance built off the 2026-07-30 guidance raise would be given back; the $65.89 high is the level a re-acceleration has to take out.

Catalyst Calendar (next 30 days)

• 2026-08-16 to 2026-09-15 — no confirmed company-specific event. This is the notable feature of the calendar: the two events that carried the tape (merger report, FDA action) are both resolved.
• 2026-09-30 — PDUFA date, Camzyos (mavacamten) sNDA for adolescents 12 to <18 with symptomatic obstructive HCM. Priority Review; SCOUT-HCM met its primary endpoint.
• ~2026-10-29 (est.) — Q3 2026 results. First independent check on the $49.000–50.000B / $6.75–7.00 FY ranges, on the 20–25% Eliquis growth outlook, and the first opportunity for a ZENBEXUS launch datapoint.

What Would Change Our Mind

The structural claim is that the 2026-07-30 guidance reset marks a durable step-up in run-rate rather than first-half timing. What would falsify it, in order of how directly it reads: FY2026 sales guidance walked back toward $46.000–47.500B at the Q3 print, or implied H2 revenue below the Q2 $12.973B run-rate; the Eliquis 20–25% growth range trimmed; management framing 2027 as a step-down year.

On price, a daily close below $61 gives back the post-guidance-raise advance and returns the discussion to loss-of-exclusivity math with no dated catalyst to interrupt it. A second condition: the 2026-09-30 Camzyos adolescent PDUFA passing without approval removes the last dated pipeline event before late October, leaving the name to trade on cohort beta and drug-pricing headlines.

A separate falsifier runs the other way and would require re-rating the bull case upward: a confirmatory EXCALIBER-RRMM PFS result converting ZENBEXUS to full approval, or a first ZENBEXUS revenue line at the Q3 print that scales like Camzyos did.

Correlation Notes

• Large-cap pharma cohort beta: moves with LLY, MRK, PFE, ABBV and the XLV/IHE complex on drug-pricing and tariff headlines. The 2026-08-10 $2.3B Houston commitment is a company-specific hedge against that shared exposure.
• Eliquis sits in the first CMS negotiation cohort with prices effective 2026-01-01, so BMY carries above-cohort sensitivity to any Medicare pricing headline.
• Camzyos and Cytokinetics' aficamten now trade as an explicit pair on the same patent docket (D. Del., filed 2026-08-13); adverse rulings for one are relevant to the other.
• Recurring AstraZeneca merger press reintroduces correlation to the pharma M&A basket without any confirmed transaction behind it.
• Effectively no correlation to the AI/semis complex; on risk-off days the name has traded with the defensive dividend cohort rather than the tape.